This CPB has been revised to state that durvalumab (Imfinizi) is considered medically necessary for the treatment of unresectable stage II non-small cell lung cancer (NSCLC). This CPB has been updated with the following: (i) additional dosing recommendations for durvalumab (Imfinzi), (ii) created subheaders, (iii) reorganized the policy format, and (iv) added additional background information and references.